恩格列净所致酮症酸中毒：一种范式转变——病例报告及文献综述
Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
作者信息
Hernandez-Quiles Carlos, Ramirez-Duque Nieves, Acosta-Delgado Domingo
机构信息
Internal Medicine Department, Hospitales Universitarios Virgen del Rocio, Sevilla, Spain.
Endocrinology Department, Hospitales Universitarios Virgen del Rocio, Sevilla, Spain.
出版信息
Curr Diabetes Rev. 2019;15(4):259-262. doi: 10.2174/1573399814666180726114044.
INTRODUCTION
Sodium-glucose cotransporter 2(SGLT2)-inhibitors are new antihyperglycemic agents that have shown a reduction in cardiovascular events in type 2 diabetes mellitus. Recent warnings have been developed about an increased risk of euglycemic and moderate hyperglycemic diabetic ketoacidosis with the use of SGLT2 inhibitors, but its real incidence is not available yet.
CASE REPORT
We present a case of DKA with moderate hyperglycemia in a patient treated with metformin and empagliflozin.
CONCLUSION
DKA in patients treated with SGLT2 inhibitors can be presented as euglycemic and moderated hyperglycemia. This special presentation poses a physician's challenge.
引言
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是新型抗高血糖药物，已显示可降低2型糖尿病患者的心血管事件风险。最近有关于使用SGLT2抑制剂会增加正常血糖和中度高血糖性糖尿病酮症酸中毒风险的警告，但实际发病率尚不清楚。
病例报告
我们报告一例在接受二甲双胍和恩格列净治疗的患者中发生的中度高血糖性糖尿病酮症酸中毒病例。
结论
使用SGLT2抑制剂治疗的患者发生的糖尿病酮症酸中毒可能表现为正常血糖和中度高血糖。这种特殊表现给医生带来了挑战。
Zotero 插件